Lilly Continues Buying Spree With Three Vaccine Firm Takeouts
Bringing it to 10 M&A transactions during the first five months of 2026, Lilly has agreed to acquire Curevo, LimmaTech and Vaccine Company for as much as $3.8bn, including earnouts.
Scrip - May 26, 2026

Finance Watch: Asia IPO Numbers Attempting To Catch Up With US Offerings
Public Company Edition: After three drug developer IPOs in Hong Kong and Korea in Q1, there have been three in Asia halfway through Q2, with HanchorBio listing in Taiwan soon. Also, RA Capital launched a SPAC, while Relay raised $275m and Immix grossed $150m in FOPOs.
Scrip - May 26, 2026

All Eyes On ABTECT After More Positive Data On Abivax’s Obefazimod
Analysts claim the French biotech is leading the oral IBD landscape and are waiting for a mega-deal centered on the miR-124 up-regulator.
Scrip - May 26, 2026

Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 26, 2026

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data
While early data for VERVE-102 mark another step in Lilly's push into cardiovascular gene editing, analysts question the need for a one-and-done therapy to lower LDL-C given existing treatment options.
Scrip - May 26, 2026

In Case You Missed It: ASCO Preview
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 26, 2026

Impact Of China’s New Data Protection On Corporate Strategies, Deals
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026

Roche Adds Liver Disease Panel To Navify, Covering Full CLD Care Pathway From Fibrosis to Cancer
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026

Mercury Rises As US Skin-Lightening Concern
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026

Irish CJEU Referral Offers Route To Challenge UWWTD
The Irish High Court’s referral to the CJEU of questions over the validity of the EU Urban Wastewater Treatment Directive’s extended producer responsibility scheme offers the off-patent industry another route to challenge the controversial legislation.
Generics Bulletin - May 26, 2026

Lupin Downs Otsuka On US Jynarque Appeal
Lupin has prevailed at the Federal Circuit in a patent dispute involving Otsuka’s Jynarque, preserving a non-infringement win and invalidating asserted tolvaptan synthesis claims.
Generics Bulletin - May 26, 2026

The Modernization Of Entity Matching: A Strategic Imperative For The Life Sciences Sector
The integration of advanced machine learning and generative AI into entity matching pipelines is increasingly recognized for its value in modernizing patient record linkage, unlocking real-world evidence, optimizing clinical trials and driving commercial success.
In Vivo - May 26, 2026

Against Specialist Tide, Anthropic Backs A Generalist Claude for Biopharma’s R&D Stack
Anthropic is betting that a generalist Claude trained on biology, backed by a $400m biotech acquisition, an in-house wet lab and a Novartis-CEO board seat, can become biopharma’s end-to-end AI partner for drug discovery.
In Vivo - May 26, 2026